Skip to main content
An official website of the United States government
Email

Trastuzumab and hyaluronidase-oysk (Herceptin-Hylecta)

Agent Description

HERCEPTIN HYLECTA™ is a combination of trastuzumab, a HER2/neu receptor antagonist, and hyaluronidase, an endoglycosidase, indicated as adjuvant treatment of HER2-overexpressing breast cancer.

Mechanism of Action

Trastuzumab is a recombinant humanized immunoglobulin  (Ig) G1κ monoclonal antibody, which targets the human epidermal growth factor receptor 2 (HER2, also known as c-erbB-2), a transmembrane glycoprotein with intrinsic tyrosine kinase activity. Trastuzumab binds to distinct HER2 epitopes without competing and has complementary mechanisms for disrupting HER2 signaling. This results in augmented anti-proliferative activity in vitro and in vivo when trastuzumab is administered.

Classification

Fully human immunoglobulin monoclonal antibody produced in Chinese hamster ovary cells.

Molecular Target

Human epidermal growth factor receptor 2 (HER2, also known as c-erbB-2)

Monograph

The product for SC delivery of trastuzumab has been developed for the treatment of HER2-positive breast cancer. It is expected that SC administration will result in a less invasive and faster administration of trastuzumab, while maintaining similar efficacy and safety to the Herceptin® IV formulation.

View the trastuzumab and hyaluronidase-oysk package insert (PDF).

Studies of Interest

Areas NOT of Interest

  • Combinations with ado-trastuzumab emtansine
  • Combinations with bevacizumab
  • Combinations with biosimilar Trastuzumab
  • Novel combinations in the absence of Phase I data

Information collaborator would like included in investigator proposals

Sponsor-investigator must indicate appropriate facilities/personnel, experience treating patients in desired research population and that they have an adequate sample size they can enroll into study, and a proven track record for conducting and publishing research. Formulary LOI proposal needs to describe if they have ongoing studies at their institution that would compete with the research population of interest during the expected patient accrual window.

If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “Trastuzumab and hyaluronidase-oysk (Herceptin-Hylecta) was originally published by the National Cancer Institute.”

Email